Disitamab vedotin (DV) is a novel anti-HER2 ADC that binds to a different epitope on HER2 compared to trastuzumab. We assessed the efficacy of DV in breast and gastric cancer cell lines and xenografts, including tumor models resistant to T-DM1 and T-DXd. Additionally, we investigated ...
231 (PB219): Optimizing treatment strategies for HER2-positive breast and gastric cancer: preclinical evaluation of disitamab vedotin, trastuzumab emtansine, trastuzumab deruxtecan, and their combinations therapies in mouse modelsdoi:10.1016/j.ejca.2024.114749N. Pourjamal...
31 Oct 2024CDE of China's NMPA accepts BLA for Disitamab vedotin for Breast cancer for review You need to be a logged in or subscribed to view this contentRequest demo(opens in a new window) If your organization or you do not have a subscription, try one of the following: ...
Disitamab Vedotin isChina'sfirst domestically made antibody-drug conjugate indicated for HER2-expressing locally advanced or metastatic gastric cancer. According to Frost & Sullivan, gastric cancer is one of the leading causes of cancer death...
CAS号2136633-23-1货号BCP44433 中文名纬迪西妥单抗 英文名Disitamab Vedotin 中文别名维迪西妥单抗; 英文别名RC48; SMILES 化学名称 分子式分子量 纯度98%配送惯例下常温包邮 产品描述Disitamab vedotin is an HER2-directed antibody-drug conjugate, emerging as an effective strategy for cancer therapy, which...
11.Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.Drug Deliv. 2022;29:1335-1344.[RCA][PubMed][DOI][Full Text][Full Text (PDF)][Cited by in Crossref: 7][Cited by inRCA: 121][Article Influence: 40.3][Re...
ai®) and Disitamab Vedotin (trade name: Aidexi®) have been included in the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021), to treat systemic lupus erythematosus (SLE) and locally advanced or metastatic gastric cancer, ...
5528#Background:Disitamab Vedotin (DV) is a HER2-targeted antibody-drug conjugate (ADC), and is approved in HER2-expressing gastric cancer and locally advanced or metastatic urothelial carcinoma. HER2 also shows certain expression in Gynecological malignant tumors. A phase 2, open-label, ...
Case reportBACKGROUND In patients with human epidermal growth factor receptor 2(HER2)-overex-pressing gastric cancer(GC),the combination of HER2 targeting and a standard first-line chemotherapy regimen has been demonstrated to significantly improve their prognosis.However,in a proportion of patients,...
Novel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug toxicities of disitamab vedotin (RC48) plus immune checkpoint inhibitors(ICIs) and RC48 as third-line therapies and beyond for advanced and metastatic gastric ...